Hofseth BioCare ASA (HBC.OL)
NOK 1.95
(0.0%)
NOK 1.95
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -106.68 Million NOK | 22.35% |
| 2022 | -137.38 Million NOK | -8.64% |
| 2021 | -126.46 Million NOK | -23.87% |
| 2020 | -102.09 Million NOK | -14.44% |
| 2019 | -89.2 Million NOK | -5.24% |
| 2018 | -84.76 Million NOK | -414.53% |
| 2017 | -16.47 Million NOK | 88.83% |
| 2016 | -147.45 Million NOK | -47.16% |
| 2015 | -100.19 Million NOK | -49.73% |
| 2014 | -66.91 Million NOK | -28.35% |
| 2013 | -52.13 Million NOK | 29.41% |
| 2012 | -73.86 Million NOK | -288.0% |
| 2011 | -19.03 Million NOK | -102.79% |
| 2010 | -9.38 Million NOK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -17.56 Million NOK | 39.45% |
| 2024 Q1 | -29 Million NOK | 44.1% |
| 2023 Q2 | 5.76 Million NOK | 115.23% |
| 2023 Q4 | -51.89 Million NOK | -128.46% |
| 2023 Q3 | -22.71 Million NOK | -494.08% |
| 2023 FY | -106.68 Million NOK | 22.35% |
| 2023 Q1 | -37.83 Million NOK | 1.14% |
| 2022 Q4 | -38.27 Million NOK | -9.15% |
| 2022 Q3 | -35.06 Million NOK | -23.54% |
| 2022 Q2 | -28.38 Million NOK | 20.42% |
| 2022 FY | -137.38 Million NOK | -8.64% |
| 2022 Q1 | -35.66 Million NOK | 8.99% |
| 2021 Q2 | -24.63 Million NOK | 8.22% |
| 2021 Q1 | -26.84 Million NOK | 13.59% |
| 2021 Q3 | -37.79 Million NOK | -53.39% |
| 2021 Q4 | -39.18 Million NOK | -3.7% |
| 2021 FY | -126.46 Million NOK | -23.87% |
| 2020 FY | -102.09 Million NOK | -14.44% |
| 2020 Q1 | -17.88 Million NOK | 46.51% |
| 2020 Q3 | -32.86 Million NOK | -62.11% |
| 2020 Q2 | -20.27 Million NOK | -13.35% |
| 2020 Q4 | -31.06 Million NOK | 5.47% |
| 2019 Q4 | -33.43 Million NOK | -83.02% |
| 2019 Q2 | -16.86 Million NOK | 18.26% |
| 2019 Q1 | -20.63 Million NOK | 12.0% |
| 2019 Q3 | -18.26 Million NOK | -8.29% |
| 2019 FY | -89.2 Million NOK | -5.24% |
| 2018 Q2 | -18.83 Million NOK | 15.01% |
| 2018 FY | -84.76 Million NOK | -414.53% |
| 2018 Q1 | -22.16 Million NOK | -71.91% |
| 2018 Q4 | -23.45 Million NOK | -15.41% |
| 2018 Q3 | -20.32 Million NOK | -7.9% |
| 2017 Q3 | -12.02 Million NOK | 37.7% |
| 2017 FY | -16.47 Million NOK | 88.83% |
| 2017 Q4 | -12.89 Million NOK | -7.17% |
| 2017 Q1 | 27.75 Million NOK | 212.28% |
| 2017 Q2 | -19.3 Million NOK | -169.57% |
| 2016 Q4 | -24.71 Million NOK | 43.79% |
| 2016 FY | -147.45 Million NOK | -47.16% |
| 2016 Q2 | -50.58 Million NOK | -79.48% |
| 2016 Q1 | -28.18 Million NOK | 33.36% |
| 2016 Q3 | -43.96 Million NOK | 13.08% |
| 2015 Q3 | -16.31 Million NOK | 28.19% |
| 2015 Q4 | -42.29 Million NOK | -159.26% |
| 2015 FY | -100.19 Million NOK | -49.73% |
| 2015 Q1 | -18.87 Million NOK | 28.49% |
| 2015 Q2 | -22.71 Million NOK | -20.33% |
| 2014 FY | -66.91 Million NOK | -28.35% |
| 2014 Q4 | -26.39 Million NOK | -90.88% |
| 2014 Q3 | -13.82 Million NOK | -5.69% |
| 2014 Q2 | -13.08 Million NOK | 3.84% |
| 2014 Q1 | -13.6 Million NOK | -59.33% |
| 2013 Q1 | -17.65 Million NOK | 61.08% |
| 2013 Q2 | -17.4 Million NOK | 1.42% |
| 2013 Q3 | -8.53 Million NOK | 50.96% |
| 2013 Q4 | -8.54 Million NOK | -0.05% |
| 2013 FY | -52.13 Million NOK | 29.41% |
| 2012 Q1 | -13.62 Million NOK | -113.96% |
| 2012 Q3 | -7.11 Million NOK | 27.19% |
| 2012 Q4 | -45.36 Million NOK | -537.18% |
| 2012 FY | -73.86 Million NOK | -288.0% |
| 2012 Q2 | -9.77 Million NOK | 28.26% |
| 2011 Q1 | -4.1 Million NOK | 27.66% |
| 2011 Q4 | -6.37 Million NOK | -47.12% |
| 2011 FY | -19.03 Million NOK | -102.79% |
| 2011 Q3 | -4.32 Million NOK | -2.37% |
| 2011 Q2 | -4.22 Million NOK | -3.0% |
| 2010 Q4 | -5.67 Million NOK | -477.9% |
| 2010 FY | -9.38 Million NOK | 0.0% |
| 2010 Q3 | -982.3 Thousand NOK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Arctic Bioscience AS | -45.51 Million NOK | -134.393% |
| Aqua Bio Technology ASA | -19.11 Million NOK | -458.177% |
| ArcticZymes Technologies ASA | 19.42 Million NOK | 649.205% |
| BerGenBio ASA | -190.4 Million NOK | 43.969% |
| PCI Biotech Holding ASA | -20.31 Million NOK | -425.144% |
| Thor Medical ASA | -26.56 Million NOK | -301.653% |
| Ultimovacs ASA | -189.23 Million NOK | 43.625% |